Coloplast Valuation

Is CBHD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CBHD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CBHD (€119) is trading below our estimate of fair value (€203.73)

Significantly Below Fair Value: CBHD is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CBHD?

Key metric: As CBHD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CBHD. This is calculated by dividing CBHD's market cap by their current earnings.
What is CBHD's PE Ratio?
PE Ratio39.7x
EarningsDKK 5.05b
Market CapDKK 200.37b

Price to Earnings Ratio vs Peers

How does CBHD's PE Ratio compare to its peers?

The above table shows the PE ratio for CBHD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21x
PHH2 Paul Hartmann
11.7xn/a€713.9m
SHL Siemens Healthineers
28.3x14.2%€55.0b
AFX Carl Zeiss Meditec
25.5x16.3%€5.2b
FME Fresenius Medical Care
18.6x19.3%€12.2b
CBHD Coloplast
39.7x12.9%€200.4b

Price-To-Earnings vs Peers: CBHD is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the peer average (21x).


Price to Earnings Ratio vs Industry

How does CBHD's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CBHD 39.7xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CBHD is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the European Medical Equipment industry average (29.7x).


Price to Earnings Ratio vs Fair Ratio

What is CBHD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBHD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.7x
Fair PE Ratio28.4x

Price-To-Earnings vs Fair Ratio: CBHD is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the estimated Fair Price-To-Earnings Ratio (28.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CBHD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€116.80
€122.49
+4.9%
11.0%€140.82€93.88n/a21
Oct ’25€118.00
€122.54
+3.8%
11.0%€142.18€93.89n/a20
Sep ’25€124.00
€122.17
-1.5%
11.3%€142.09€93.84n/a20
Aug ’25€120.25
€121.42
+1.0%
11.0%€142.07€95.16n/a20
Jul ’25€111.50
€120.02
+7.6%
10.5%€142.08€95.17n/a20
Jun ’25€108.45
€121.95
+12.4%
10.2%€142.06€95.16n/a19
May ’25€113.90
€122.93
+7.9%
10.9%€142.09€93.83n/a19
Apr ’25€123.55
€120.32
-2.6%
10.3%€142.13€93.86n/a19
Mar ’25€121.95
€116.96
-4.1%
10.1%€134.16€93.91n/a19
Feb ’25€107.10
€110.46
+3.1%
9.8%€129.01€84.62n/a19
Jan ’25€104.10
€109.56
+5.2%
10.3%€129.07€84.66n/a18
Dec ’24€107.00
€109.69
+2.5%
10.1%€129.05€84.65n/a18
Nov ’24€98.66
€113.71
+15.3%
9.2%€131.29€91.90€116.8018
Oct ’24€100.70
€116.05
+15.2%
9.9%€134.12€92.01€118.0017
Sep ’24€106.05
€121.79
+14.8%
10.1%€143.59€96.62€124.0015
Aug ’24€111.35
€124.66
+12.0%
9.9%€143.60€96.63€120.2516
Jul ’24€114.50
€122.90
+7.3%
11.0%€143.65€92.63€111.5016
Jun ’24€117.15
€122.95
+4.9%
11.0%€143.71€92.67€108.4516
May ’24€131.15
€122.53
-6.6%
10.0%€140.25€92.61€113.9016
Apr ’24€121.55
€121.15
-0.3%
9.8%€140.26€92.61€123.5516
Mar ’24€108.30
€121.26
+12.0%
10.2%€140.31€92.64€121.9515
Feb ’24€113.55
€121.99
+7.4%
9.7%€140.50€92.77€107.1015
Jan ’24€110.20
€123.56
+12.1%
7.7%€140.52€107.31€104.1015
Dec ’23€113.60
€126.00
+10.9%
11.4%€164.59€107.31€107.0014
Nov ’23€113.30
€127.41
+12.5%
12.2%€164.45€106.14€98.6614

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies